There is currently no text in this page. You can search for this page title in other pages, or search the related logs, but you do not have permission to create this page.
Category:CPC A61K31/513
Pages in category "CPC A61K31/513"
The following 35 pages are in this category, out of 35 total.
2
- 20250177396. Polo-like Kinase 4 (p (Repare Therapeutics .)
- 20250177397. Inhibitors Mptp (NRG Therapeutics)
- 20250177398. Ca (RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY)
- 20250186443. Valacyclovir Celecoxi (Unknown Organization)
- 20250195520. Combination Therapy Using (NAVIRE PHARMA, .)
- 20250205236. Formulations (Deciphera Pharmaceuticals, LLC)
- 20250205237. Methods Trea (Deciphera Pharmaceuticals, LLC)
- 20250213563. Substituted Pyrimidin-4(3h (NAVIRE PHARMA, .)
- 20250213564. Compositions Methods Treatment Alzheimer's Disease Other Neurogene (THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK)
- 20250213565. Treatment Hcm Pyrimidi (MyoKardia, .)
A
- AbbVie Inc. Patent Application Trends in 2025
- Arizona Board of Regents on behalf of Arizona State University Patent Application Trends in 2025
- Arizona Board of Regents on Behalf of Arizona State University Patent Application Trends in 2025
- ASTELLAS PHARMA INC. Patent Application Trends in 2024
- ASTRAZENECA AB Patent Application Trends in 2025
- AstraZeneca AB Patent Application Trends in 2025
C
F
T
- TAKEDA PHARMACEUTICAL COMPANY LIMITED Patent Application Trends in 2024
- THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM Patent Application Trends in 2024
- The Board of Regents of the University of Texas System Patent Application Trends in 2024
- The Board of Trustees of the Leland Stanford Junior University Patent Application Trends in 2024
- The University of Toledo Patent Application Trends in 2024